REQUEST A DEMO
Total
USD $0.00
Search more companies

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (China)

Main Activities: Pharmaceutical and Medicine Manufacturing | Navigational, Measuring, Electromedical, and Control Instruments Manufacturing | Management of Companies and Enterprises
Secondary Activities: Drugs and Druggists' Sundries Merchant Wholesalers | Pharmacies and Drug Stores
Full name: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Profile Updated: September 19, 2021
Buy our report for this company USD 29.95 Most recent financial data: 2020 Available in: English & Chinese Download a sample report

The origin of the Group dates back to 1983 when GPGC wasestablished as a State-owned enterprise to supervise thepharmaceutical industry in the Guangzhou Municipality and toperform the business administration function relating toState-owned entities engaged in the pharmaceuticalmanufacturing and trading businesses in the GuangzhouMunicipality under the jurisdiction of the GuangzhouMunicipal Government. In August 1996, pursuant to theapproval granted by the Guangzhou Municipality Government,GPGC was transformed into GZPHL, which took over thebusiness administration function of GPGC, and GPAB, whichtook over the industry supervision function of GPGC. As aresult, GZPHL inherited the businesses of 31 pharmaceuticalentities, including the Eleven Enterprises, previouslycontrolled by GPGC and was authorised by Guangzhou StateAssets Bureau to manage the State-owned assets of these 31pharmaceutical entities. The Company was established as ajoint stock limited company with limited liability on 1stSepetember, 1997. H shares of the Company were listed onHong Kong Stock Exchange on 31th October, 1997.

Headquarters
45 Shamian N. St. Guangzhou Guangdong
Guangzhou; Guangdong; Postal Code: 510130

Contact Details: Purchase the Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited report to view the information.

Website: http://www.gybys.com.cn

Basic Information
Total Employees:
Purchase the Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited report to view the information.
Outstanding Shares:
Purchase the Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited report to view the information.
Registered Capital:
Purchase the Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited report to view the information.
Financial Auditors:
Purchase the Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited report to view the information.
Ratings:
Purchase the Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited report to view the information.
Incorporation Date:
September 01, 1997
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
Executive Director
Purchase this report to view the information.
Executive Director
Purchase this report to view the information.
Executive Director
Purchase this report to view the information.
Chairman of the Supervisory Board
Ownership Details
Purchase this report to view the information.
45.04%
Purchase this report to view the information.
13.52%
Purchase this report to view the information.
4.51%
Purchase this report to view the information.
3.75%
Purchase this report to view the information.
2.91%
Subsidiaries
Baiyunshan Welling Pharmaceutical Co., Ltd.
100%
Gansu Guangyao Baiyunshan Traditional Chinese Medicine Technology Co., Ltd.
100%
Guangyao (Zhuhai Hengqin) Pharmaceutical Industrial Park Co., Ltd.
100%
Company Performance
Financial values in the chart are available after Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency CNY. Absolute financial data is included in the purchased report.
Net sales revenue
18.57%
Total operating revenue
18.96%
Operating profit (EBIT)
43.64%
EBITDA
48.11%
Net Profit (Loss) for the Period
40.55%
Total assets
13.6%
Total equity
11.36%
Operating Profit Margin (ROS)
1.57%
Net Profit Margin
1.14%
Return on Equity (ROE)
1.83%
Debt to Equity Ratio
6.88%
Quick Ratio
0.06%
Cash Ratio
0.04%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?